Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Hepatol. Nov 27, 2012; 4(11): 291-298
Published online Nov 27, 2012. doi: 10.4254/wjh.v4.i11.291
Table 1 Clinical characteristics, demographic data and laboratory data of 3857 cirrhotic patients
ParameterAll patients (n = 3857)Survivors (n = 2375)Non-survivors (n = 1482)P value
Age, yr60.73 ± 14.0559.02 ± 14.0263.48 ± 13.65< 0.001
Male, n (%)2665 (69.1)1651 (69.52)1014 (68.42)NS (0.474)
Hepatoma, n (%)1385 (35.9)653 (27.5)732 (49.4)< 0.001
Cause of liver cirrhosis, n (%)< 0.001
Hepatitis C930 (24.1)568 (23.9)362 (24.4)-
Hepatitis B1090 (28.3)631 (26.6)459 (31)-
Alcoholic813 (21.1)580 (24.4)233 (15.7)-
Hepatitis C + hepatitis B106 (2.7)70 (2.9)36 (2.4)-
Hepatitis C + alcohol60 (1.6)39 (1.6)21 (1.4)-
Hepatitis B + alcohol191 (5)127 (5.3)64 (4.3)-
Hepatitis C + hepatitis B + alcohol33 (0.9)19 (0.8)14 (0.9)-
Not hepatitis C, hepatitis B or alcohol634 (16.4)341 (14.4)293 (19.8)-
Ascites, n (%)1861 (48.2)825 (34.7)1036 (69.9)< 0.001
Hepatic encephalopathy, n (%)1097 (28.4)434 (18.3)663 (44.7)< 0.001
Child–Pugh points8.36 ± 2.577.11 ± 1.9710.37 ± 2.1< 0.001
MELD score18.9 ± 10.2613.15 ± 5.5727.98 ± 9.36< 0.001
Albumin, 3.5-5 g/dL2.95 ± 0.733.24 ± 0.682.49 ± 0.55< 0.001
Total bilirubin, 0.3-1.2 mg/dL5.18 ± 8.162.24 ± 3.579.89 ± 10.81< 0.001
INR1.89 ± 1.751.43 ± 0.432.72 ± 2.55< 0.001
BUN, 8-12 mg/dL34.47 ± 35.5517.63 ± 15.5261.44 ± 41.49< 0.001
Creatinine, 0.4-1.2 mg/dL1.94 ± 1.911.27 ± 1.353.01 ± 2.17< 0.001
eGFR, mL/(min∙1.73 m-2) (MDRD-4)63.17 ± 46.1279.14 ± 37.437.57 ± 47.24< 0.001
eGFR, mL/(min∙1.73 m-2) (MDRD-6)54.87 ± 38.2570.85 ± 33.2929.32 ± 31.16< 0.001
eGFR, mL/(min∙1.73 m-2) (CKD-EPI)65.39 ± 37.4982.11 ± 30.2838.59 ± 31.99< 0.001
Table 2 Univariate and multivariate logistic regression analyses of the various parameters in predicting in-hospital mortality
ParameterBeta coefficientStandard errorOdds ratios (95% CI)P value
Univariate logistic regression analysis
Age, yr0.020.001.02 (1.02-1.03)< 0.001
Hepatoma0.950.072.57 (2.25-2.95)< 0.001
Ascites1.470.074.36 (3.80-5.02)< 0.001
Hepatic encephalopathy1.290.073.62 (3.13-4.19)< 0.001
Cause of liver cirrhosis (reference group: NBNCNA)
Hepatitis C-0.300.100.74 (0.61-0.91)0.004
Hepatitis B-0.170.100.85 (0.70-1.03)NS (0.098)
Alcoholic-0.760.110.47 (0.38-0.58)< 0.001
Hepatitis C + hepatitis B-0.510.220.60 (0.39-0.92)0.020
Hepatitis C + alcoholic-0.530.170.59 (0.42-0.82)0.002
Hepatitis B + alcoholic-0.150.360.86 (0.42-1.74)NS (0.670)
Hepatitis C + hepatitis B + alcoholic-0.470.280.63 (0.36-1.09)NS (0.098)
Child–Pugh points0.670.021.95 (1.87-2.03)< 0.001
MELD score0.220.011.25 (1.23-1.27)< 0.001
BUN, mg/dL0.070.001.07 (1.06-1.07)< 0.001
Creatinine, mg/dL0.720.032.05 (1.93-2.18)< 0.001
eGFR, mL/(min∙1.73 m-2) (MDRD-4)-0.040.000.97 (0.96-0.97)< 0.001
eGFR, mL/(min∙1.73 m-2) (MDRD-6)-0.050.000.95 (0.95-0.96)< 0.001
eGFR, mL/(min∙1.73 m-2) (CKD-EPI)-0.040.000.97 (0.96-0.96)< 0.001
Albumin, g/dL-1.970.070.14 (0.12-0.16)< 0.001
Total bilirubin, mg/dL0.200.011.22 (1.20-1.25)< 0.001
INR1.740.085.70 (4.87-6.67)< 0.001
Multivariate logistic regression analysis
Age, yr0.030.011.03 (1.01-1.04)< 0.001
Hepatoma0.950.132.60 (2.02-3.34)< 0.001
Cause of liver cirrhosis (reference group: NBNCNA)
Hepatitis C-0.190.180.83 (0.58-1.18)NS (0.299)
Hepatitis B-0.280.190.76 (0.52-1.10)NS (0.139)
Alcoholic-0.210.220.81 (0.52-1.25)NS (0.342)
Hepatitis C + hepatitis B-1.030.400.36 (0.16-0.78)0.010
Hepatitis C + alcoholic-0.790.350.46 (0.23-0.90)0.023
Hepatitis B + alcoholic0.320.571.38 (0.45-4.22)NS (0.576)
Hepatitis C + hepatitis B + alcoholic0.540.471.71 (0.68-4.29)NS (0.354)
MELD score0.140.031.14 (1.09-1.20)< 0.001
BUN, mg/dL0.040.001.05 (1.04-1.05)< 0.001
eGFR, mL/(min∙1.73 m-2) (MDRD-4)0.030.011.03 (1.02-1.04)< 0.001
eGFR, mL/(min∙1.73 m-2) (MDRD-6)-0.030.010.97 (0.95-0.99)< 0.001
Albumin, g/dL-1.240.130.29 (0.22-0.38)< 0.001
INR0.240.101.27 (1.04-1.54)0.019
Table 3 Relationship between estimated glomerular filtration rate, total bilirubin, international normalized ratio and model for end-stage liver disease score as a predictor of in-hospital mortality
ModelVariableOdds ratio (95% CI)P valueχ2-2 Log Likelihood
Model 1MELD1.25 (1.23-1.27)< 0.0012198.322773.90
Model 2Total bilirubin12.25 (2.05-2.48)< 0.0012161.452810.77
INR16.14 (4.56-8.27)< 0.001
eGFR (MDRD-4)10.22 (0.20-0.25)< 0.001
Model 3Total bilirubin12.17 (1.97-2.40)< 0.0012293.822664.79
INR15.95 (4.39- 8.06)< 0.001
eGFR (MDRD-6)10.19 (0.17-0.22)< 0.001
Model 4Total bilirubin12.26 (2.05-2.48)< 0.0012199.162773.07
INR16.28 (4.65-8.49)< 0.001
eGFR (CKD-EPI)10.20 (0.18-0.23)< 0.001
Table 4 Comparison of different models for end-stage liver disease equations for the prediction of in-hospital mortality
EquationsOdds ratio (95% CI)P valueχ2-2 Log Likelihood
MELD1.25 (1.23-1.27)< 0.0012198.322773.90
MELD-MDRD-41.27 (1.26-1.29)< 0.0012147.932824.30
MELD-MDRD-61.29 (1.27-1.31)< 0.0012254.882703.72
MELD-CKD-EPI1.28 (1.26-1.30)< 0.0012185.012787.21
Table 5 The difference between the model for end-stage liver disease and model for end-stage liver disease-modification of diet in renal disease-6 scores of differentially obtained estimated glomerular filtration rate for the prediction of in-hospital mortality
eGFREquationsOdds ratio (95% CI)P valueχ2-2 Log Likelihood
≥ 90MELD1.17 (1.13-1.21)< 0.00199.45609.51
MELD-MDRD-61.20 (1.16-1.24)< 0.001114.55588.67
60-89MELD1.22 (1.18-1.26)< 0.001185.77636.17
MELD-MDRD-61.27 (1.22 -1.32)< 0.001214.60606.45
30-59MELD1.21 (1.17-1.24)< 0.001283.21755.92
MELD-MDRD-61.26 (1.22-1.30)< 0.001312.75725.22
15-29MELD1.25 (1.19-1.30)< 0.001163.72369.37
MELD-MDRD-61.31 (1.24-1.39)< 0.001182.49350.59
< 15MELD1.36 (1.27-1.45)< 0.001190.62311.89
MELD-MDRD-61.30 (1.23-1.39)< 0.001164.66337.42